FDA Grants Accelerated Approval to Glofitamab-gxbm

On June 15, the US Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.

For more information read the FDA announcement and the Genentech announcement.

Posted 6/20/2023